OBJECTIVE: Fatty acid oxidation has been implicated in amelioration of obesity by burning off excessive accumulated lipid. BPR697, a peripheral cannabinoid receptor 1 (CB1) antagonist, elevated fat oxidation without added energy expenditure. Its impact on food intake, body weight changes and metabolic alterations were examined in rats fed standard chow and in diet-induced obesity (DIO) mice. MATERIALS AND METHODS: CB1 agonist-induced hypothermia and analgesia responses were measured to examine the brain activity of BPR697. The acute effects of BPR697 on food intake, body weight change and post-absorptive metabolic profiles were investigated in rats. Energy utilization with BPR697 was examined by indirect calorimetry. Chronic treatment of DIO mice was used to evaluate the long-term effects of BPR697. RESULTS: Distribution of BPR697 was significantly biased in favor of the periphery instead of the brain, as shown by its low brain/plasma concentration ratio and confirmed by the negative response of BPR697 in CB1 agonist-induced hypothermia and analgesia. When administered to rats at 20 mg kg À1 , BPR697 showed a unique spectrum of effects with significant weight loss without altered food intake. Furthermore, BPR697 increased serum levels of free fatty acids and ketone bodies and reduced hepatic lipid accumulation with preservation of liver glycogen in postprandial rats. Indirect calorimetric profiling of BPR697 revealed a similar trend, shifting whole-body energy catabolism toward fat oxidation, but without elevated energy expenditure. In DIO mice with chronic treatment, animals treated with BPR697 at 20 mg kg À1 resisted weight gain and showed a reduction of high-fat-induced cardiometabolic abnormalities such as hyperglycemia, abdominal fat and liver steatosis. CONCLUSION: The induction of fatty acid oxidation without concomitant elevation of energy expenditure by the peripheral CB1 antagonist BPR697 is sufficient to cause substantial weight loss in chow-fed rats. In the presence of high-dietary fat intake, BPR697 resists weight gain and alleviates obesity-related cardiometabolic risk factors. (2012) 36, 999 --1006; doi:10.1038/ijo.2011.171; published online 6 September 2011
INTRODUCTION
Energy homeostasis, the balance between energy intake and energy expenditure, is regulated by coordinated interaction between the central nervous system and peripheral tissues. Elucidation of the metabolic factors influencing energy balance, and lipid and glucose metabolism has been a major focus of research interest, and many studies of the underlying mechanisms have revealed the importance of communication between the central nervous system and the periphery. 1--3 Among various factors involved in energy balance, endocannabinoids (for example, anandamide and 2-arachidonoylglycerol) mediate a positive energy balance via activation of their receptor, cannabinoid receptor 1 (CB1). The brain CB1 receptor, a G proteincoupled receptor, is present at a high level in brain tissue, and enhances appetite and modulates energy expenditure primarily via neuronal actions. 4--7 On the other hand, the CB1 receptor found in many peripheral tissues involved in metabolism, such as liver, adipose tissue, skeletal muscle, pancreas and the gastrointestinal tract, promotes anabolic pathways, such as de novo lipogenesis and glucose uptake, to regulate energy homeostasis. 5,8--11 The endocannabinoid system is dysregulated after chronic perturbation of energy balance, as can be seen in mice fed a high-fat diet, and in obese and diabetic patients, 10, 12, 13 thus contributing to the exacerbation of these disorders and the associated cardiometabolic indices.
Reports on the blockade of CB1 receptor by potent and selective CB1 antagonists, such as rimonabant and taranabant, reveal that they not only function centrally to control food intake but also exerts a significant influence on peripheral tissues with a concurrent increase in oxygen consumption and resting energy expenditure, and a significant decrease in respiratory quotient. 6,9,14--17 These findings, along with the transient effect on appetite suppression, support the presence of a food intakeindependent mechanism, and the reduction in body weight during treatment with CB1 antagonists is considerably associated with increased fat oxidation. This latter effect may be attributed to the peripheral CB1 receptor rather than influence by its central counterpart, as acceleration of fatty acid oxidation has been implicated as a potential therapeutic direction to treat metabolic syndrome. 18 The beneficial physiological effects from blockade of CB1 receptors have supported its role as a therapeutic target for treating obesity and metabolic diseases. However, the psychological adverse effects resulting from the blockade of central CB1 receptors have not yet been solved. 19 Therefore, a new research direction focused on identification of peripheral CB1 compounds provides an alternative approach to minimize the pharmacological characteristics mediated by central CB1 receptors. 19, 20 Nevertheless, it remains to be elucidated whether peripheral CB1 antagonism alone can contribute a sufficient anti-obesogenic effect and lead to improvement of obesity-related metabolic indices.
BPR697 has been identified as a selective CB1 inverse agonist (CB 2 /CB 1 ¼ 42) with functional activity and ligand-binding affinity (IC 50 ) of 89.8 and 25.8 nM, respectively. 21 It exhibits a low brain to plasma concentration ratio (B/P ¼ 1/23) relative to a counterpart, rimonabant, with much higher central activity (B/P ¼ 3/1). 21 Therefore, BPR697 was used here to examine the efficacy of peripheral CB1 antagonism on whole-body energy expenditure and post-absorptive state metabolic alteration in addition to body weight and food intake changes. 
MATERIALS AND METHODS Chemicals
BPR697 [1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-phenylethynyl)thiophen-2- yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide] and SR141716 [N-(piper- idin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide hydrochloride] were synthesized in-house. CP55940 [(1R,3R, 4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclo- hexan-1-ol]
Animals and diets
All experimental protocols conducted in the study were performed in accordance with the guidelines from the Institutional Animal Care and Use Committee of National Health Research Institutes, Taiwan. Male Wistar rats and male C57BL/6 mice obtained from BioLASCO Co. Ltd., Yi-Lan, Taiwan, and National Laboratory Animal Center, Taiwan, respectively, were housed under controlled environment (21 ± 2 1C, 50 ± 10% humidity) and a 12 h/ 12 h light--dark cycle. The animals were given standard chow diet (Lab diet 5053; 13% fat, 25% protein and 62% carbohydrate; 3.07 kcal g
À1
) and water ad libitum unless specified. Compounds examined in vivo were administered by oral gavage (4 ml kg À1 for rats and 10 ml kg À1 for mice), unless specified.
Hypothermia and analgesia responses
Body temperature and tail-flick responses were measured by rectal thermometer (Natsume Seisakusyo Co., Tokyo, Japan) and tail-flick analgesia meter (Columbus Instruments, Columbus, OH, USA), respectively, in 8-week-old male C57BL/6 mice. One hour after oral administration of BPR697 or rimonabant dissolved in dimethyl sulfoxide/Tween 80/H 2 O À1 was administered to rats, and cumulative intakes at 1 and 6 h, and 1-day body weight change were measured. Data represent mean ± s.e.m. for six animals per treatment group. *Po0.05 versus control group.
(1/1/8 by volume), 1 mg kg À1 of CP55940 (10 ml kg À1 ) in saline containing 0.5% dimethyl sulfoxide was injected intraperitoneally and the effects on body temperature and analgesia were measured, respectively, at 30 and 35 min later.
Acute food intake and body weight change studies in spontaneous feeding rats
The procedure was performed as described previously. 22. In brief, compounds dissolved in ethanol/PEG 300/Tween 80/Cremophor EL (12/56/11/21 by weight) were administered orally to individually housed male Wistar rats (230--280 g) before lights were turned off. One hour later, food cages were provided and food intake was recorded after additional 1 and 6 h periods. Body weight was measured the next day.
Acute study in post-absorptive rats Male Wistar rats (310--340 g) were housed in groups of two per cage. BPR697 at 20 mg kg À1 dissolved in dimethyl sulfoxide/Tween 80/H 2 O (2/1/7 by volume) was orally administered immediately after food was removed at the beginning of the light phase. Blood was collected from the tail tip a further 2 h later. After 6 h, animals were killed by cervical decapitation, and blood and liver samples were collected.
Indirect calorimetry
Oxygen consumption rate (VO 2 ) and carbon dioxide production rate (VCO 2 ) were measured using an open-circuit indirect calorimetry system (PhysioScan Metabolic System, AccuScan Instruments, Columbus, OH, USA). After allowed to become acclimated to the metabolic chamber, 8-to 11-week-old male C57BL/6 mice were administered vehicle or compounds orally 1 h before onset of the lights-on phase. The mice were subsequently monitored in the system for 24 h. The respiratory quotient and energy expenditure (kJ min À1 ) were calculated as VCO 2 
Metabolic biochemical and tissue analysis
Serum glucose, glycerol, triglycerides and 3-hydroxybutyrate (Ranbut; Randox, UK), insulin (Mercodia, Uppsala, Sweden) and NEFA (Wako, Osaka, Japan) kits were used to measure serum concentrations according to the manufacturer's instructions. Liver lipids were extracted by the method of Folch et al. 23 and analyzed using the triglycerides kit (above). Hepatic glycogen level was determined as previously described. 24 Figure 3. Effects of BPR697 on lipid metabolism of serum and liver in post-absorptive state. BPR697 (697) at 20 mg kg À1 was administered to postprandial rats. Serum free fatty acid (a), glycerol (b), triglycerides (TG, c) and 3-hydroxybutyrate (d) levels were measured after 2 and 6 h of compound administration. Liver triglycerides (e) and free fatty acid (f ) content were measured after killing at 6 h. Data are expressed as mean ± s.e.m. for six animals per treatment group. *Po0.05 versus control group.
Statistical analysis
All the data were given as mean±s.e.m. Unpaired t-test was used to determine statistical significance of difference between means (Po0.05). PRISM software (GraphPad Software, San Diego, CA, USA) was used for all statistical calculations.
RESULTS
BPR697 on CB1-induced hypothermia and analgesia CP55940, a cannabinoid receptor agonist, acutely induces hypothermic and analgesic responses mediated by central CB1 receptors. 25 The ED 50 of rimonabant in reversing these two responses in C57BL/6 mice was 2 and 1.1 mg kg À1 , respectively (data not shown). Therefore, 2 mg kg À1 of rimonabant, a central CB1 inverse agonist, was used to compare with BPR697, a peripheral CB1 inverse agonist, at 20 and 50 mg kg À1 , at doses 10 and 25 times higher than rimonabant. Rimonabant effectively reversed CP55940-induced hypothermic and analgesic effects, but neither effect was attenuated by BPR697 at either dose applied (Figure 1 ). This result suggests BPR697 does not exert central responses even at a dose as high as 50 mg kg À1 .
Acute effect on food intake and body weight BPR697 was examined for its effects in appetite suppression and weight loss in spontaneous feeding rats. Rimonabant at 10 mg kg À1 produced significant suppression of food intake both at 1 and 6 h post-oral dose with 26 and 69% of intake remained, respectively. However, it did not differ in BPR697-treated animals at a dose of 20 mg kg À1 (Figure 2a) . The control group grew 2% of body weight the next day. On the contrary, body weight significantly decreased in animals receiving either rimonabant (À0.6%) or BPR697 (À0.9%) (Figure 2b ). This result indicates the weight loss showed in BPR697-treated animals is mediated by a food intake-independent mechanism in contrast to its central counterpart, rimonabant.
Effect on biochemical parameters in post-absorptive state Markers of lipid and carbohydrate metabolism were investigated 2 and 6 h after administration of BPR697 at 20 mg kg À1 to postprandial rats. BPR697 caused a significant elevation of free fatty acid levels (Figure 3a) . Serum glycerol levels were slightly higher, in a similar trend as the free fatty acid levels, though the effects were not significant (Figure 3b ). Serum triglycerides were elevated at 2 h, but no difference was seen later at 6 h (Figure 3c ). The level of ketone bodies in the BPR697 group stayed high throughout the postprandial period with a significant difference at 6 h (Figure 3d ). Liver free fatty acid and triglyceride levels were also decreased at the end of the 6 h postprandial period (Figures  3e and f) . On the contrary, BPR697 did not change serum glucose and insulin levels or liver glycogen reserve during the treatment period (Figures 4a--c) . These results suggest that BPR697 increases lipolysis and shifts the energy source toward lipids instead of carbohydrates during the postprandial state.
Effect on energy utilization BPR697 at 20 mg kg
À1 and rimonabant at 10 mg kg À1 were further investigated by indirect calorimetry after administration to C57BL/ 6 mice 1 h before lights-off phase. Rimonabant elevated O 2 consumption and energy expenditure significantly in the light phase, but not in the dark phase (Figures 5e and h ). The rate of CO 2 production was not changed (Figure 5f ). Respiratory quotient fell prominently during the light phase, extending to the start of the dark phase (Figure 5g) . BPR697 showed a different response. It maintained a similar level of O 2 consumption as well as energy expenditure to the wild-type mice (Figures 5a and d) . The rate of CO 2 production was significantly reduced 3 h after lights-off phase, a change that was sustained into the early dark phase (Figure 5b) . Accordingly, respiratory quotient was decreased (Figure 5c ). These results indicate both rimonabant and BPR697 shift energy utilization toward lipid oxidation, especially in the light phase. Furthermore, rimonabant alone, but not BPR697, substantially increases O 2 consumption and energy expenditure. Long-term effect in DIO mice With its observed effect of increasing fat oxidation, BPR697 was investigated in diet-induced obesity (DIO) mice to examine its chronic metabolic effects. Similar to the acute study, administration of BPR697 at both 10 and 20 mg kg À1 did not alter the daily food intake throughout the study (Figure 6a ). The animals receiving BPR697 at a dose of 10 mg kg À1 gained weight (7.9%) during the treatment term, a rate, which was similar to the vehicle control group (8.3%). When the dose of BPR697 was increased to 20 mg kg À1 , initial body weight was maintained throughout the treatment period, with a final 7.6% less than the vehicle control group (Figure 6b) . The abdominal fat mass decreased dosedependently, with a significant decrease at 20 mg kg À1 , but the subcutaneous inguinal fat mass did not change significantly (Figure 6c ). Among the serum metabolic parameters examined, serum glucose levels fell significantly, but serum insulin and triglycerides levels did not change. Liver triglycerides content was substantially reduced at both doses of BPR697 (Figures 6d--g ).
DISCUSSION
Energy homeostasis, the net difference between energy intake and energy expenditure, is modestly adjusted by changing the balance between anabolic and catabolic effector pathways. Chronic energy imbalance where energy intake exceeds energy expenditure over a long period of time results in obesity. Impaired mitochondrial function, especially defects in handling lipid substrate oxidation, may also cause imbalances in energy expenditure that lead to increased adiposity and related metabolic diseases. 26 On the contrary, effective management of fatty acid oxidation is considered a tool in resisting susceptibility to dietinduced obesity.
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BPR697 is a peripherally restricted CB1 inverse agonist, as shown by its inability to attenuate cannabinoid agonist-induced responses as well as its low brain penetration. 21 Here, administration of BPR697 did not influence food intake, either in an acute condition fed with standard chow diet or in a chronic condition with high-fat diet. This result supports the essential role of the central CB1 receptor in the regulation of food intake. However, along with other studies proposing peripheral CB1 receptor in regulation of food intake, 27 ,28 a recent study on a peripheral CB1 antagonist, AM6545, demonstrates suppression of food intake in rats and in DIO mice. 29, 30 AM6545 is a P-glycoprotein substrate, 29 but there is no evidence suggesting the same for BPR697. This disparity in pharmacokinetic properties may lead to different brain penetration affecting the outcome of a simple comparison. Furthermore, the in vitro activity of BPR697 is less potent than rimonabant, 21 a compound with similar in vitro profile to AM6545, 29 which might reduce its potency in vivo. This discordance suggests that whether peripheral CB1 receptors modulate food intake remains to be elucidated.
Although food intake was not disturbed in acute treatment with BPR697, reduction in body weight was surprisingly significant, similar to that exhibited in rimonabant-treated rats. This result suggests a food intake-independent mechanism in weight loss. Increase in energy expenditure toward a negative energy balance results in weight loss. Energy expenditure enhanced by blockade of central CB1 antagonists is primarily mediated by sympathetic activation via central nervous system action. 6, 7, 31 In contrast to rimonabant, acute treatment with BPR697 did not elevate energy expenditure, which is well correlated with its poor central nervous system penetration. This result indicates the weight loss from BPR697 is not due to enhancement of energy expenditure.
Investigation of the acute effect on energy utilization revealed a decrease in RQ value upon administration of BPR697, which reflects an increased utilization fat as an oxidation substrate. The hepatic CB1 receptor has been shown to contribute to the postprandial substrate shift toward lipid oxidation. 32 The pharmacodynamics of the BPR697 access to liver and additional peripheral tissues via circulation is expected to have a wider Figure 6 . Chronic effect of BPR697 in DIO mice. BPR697 (697) at 10 or 20 mg kg À1 was orally administered to DIO mice once daily for 28 days. Daily food intake (a), body weight change (b), adiposity (c), serum glucose (d), insulin (e), triglycerides (TG, f ) levels and liver triglycerides content (g) were measured. Abdominal fat mass shown in (c) indicates the total weight of the epididymal, retroperitoneal and perirenal fat pads. Data represent mean±s.e.m. for six to eight animals per treatment group. *Po0.05 versus high-fat control group. impact on enhancing lipid oxidation. The elevated level of serum free fatty acid, an indication of increased rate of lipolysis, after treatment with BPR697 during the postprandial state further supports an enhancement of fatty acid oxidation, as shown by the elevated serum level of b-hydroxybutyrate. The enhanced adipocytic lipolysis may be mediated by targeting to presynaptic CB1 receptors on sympathetic nerve terminals, as suggested in the study of AM6545. 29, 33 On the other hand, blockade of lipogenesis has been shown to synergistically promote fatty acid oxidation. 34 The effective reduction of hepatic lipid accumulation by BPR697 may contribute to this event. Furthermore, BPR697 preserved hepatic glycogen levels, in contrast to the reduced liver glycogen seen with rimonabant. 16, 31 These findings suggest that BPR697 may reduce lipogenesis and increase lipolysis to enhance fat oxidation, thus resulting in weight loss.
Studies on CB1 receptor-deficient mice indicate an indispensable role of CB1 receptor in the regulation of adiposity, hepatic steatosis and insulin resistance. 35 On the other hand, hepatic CB1-deficient mice resist diet-induced steatosis with improvement in insulin sensitivity but not adiposity. 32 Chronic treatment of BPR0697 at 20 mg kg À1 did not lead to any weight gain, in contrast to the weight gain seen in the high-fat diet control group, with concomitant decrease in serum glucose levels. The efficacy of BPR697 in reducing hepatic steatosis was even more substantial, with significant effects at both 10 and 20 mg kg À1 . These results of reduced hyperglycemia and hepatic fat accumulation suggest that the blockade of peripheral CB1 receptors has a considerable effect in normalization of obesity-related metabolic abnormalities, independent of food intake. These beneficial effects are coincident with AM6545, demonstrating improvement in metabolic and hormonal abnormalities in DIO mice in addition to considerable efficacy in reducing obesity. 29 Furthermore, epidemiological studies indicate visceral fat is more strongly associated with increased cardiometabolic risk than subcutaneous fat. 36, 37 A higher endocannabinoid tone is detected in the visceral fat relative to the subcutaneous fat in both human and mice. 10, 12, 13 Treatment of rimonabant exhibits a preferential loss of abdominal fat over subcutaneous fat, 38 which was also observed in the treatment with BPR697. In this regard, repeated stimulation of fatty acid oxidation in addition to inhibition of lipid accumulation decreased abdominal fat mass and hepatic lipids, as observed in other studies. 39 These results suggest peripheral CB1 antagonists may reduce the cardiometabolic risk factors as efficaciously as their centrally acting counterparts.
In conclusion, the overall effect of peripheral CB1 antagonism on fat oxidation, substrate flexibility, metabolic parameters and body weight described in this study reveals a different mechanism of lipid and glucose homeostasis, in contrast to the most-studied central CB1 antagonists. In addition, we have shown here that diet-induced obesity can be effectively managed by targeting peripheral CB1 receptors, which can have a significant impact on energy homeostasis through modulating metabolic substrate flexibility. Thus, specific peripheral CB1 receptor antagonism remains a potential target in the treatment of metabolic disorders, such as non-alcoholic fatty liver disease and type 2 diabetes, and our present study strengthens this strategy.
